Drugs / BAY 1238097
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02369029 | Mar 2015 → Jan 2016 | neoplasm | Bayer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 1238097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02369029 ↗ |
| Action | Inhibit | “A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated dose and recommended phase II dose of the BET inhibitor BAY 1238097 in patients with...” PMID 30711772 ↗ Jan 2019 |
| Route | Oral | “Oral administration twice weekly.” NCT02369029 ↗ |